bristol-myers squibb

Wall Street Predicts the Bull Market May Keep Charging

Is the bull back? Strong earnings, growing merger activity and an improved macroeconomic outlook could give the bull market plenty of room to run. The forecast will become clearer this week, when several key economic and earnings reports are scheduled to come out.

Abbott Experiments with a $450 Million Deal for Facet

Abbott Labs announced it would acquire Facet Biotech for $27 per share. The friendly deal, which will enhance Abbott's pharmaceutical pipeline, is expected to close in the second quarter of this year and has been approved by the boards of both companies.

Five Stocks That Might Beat the Market This Year

It sure is tough, but some stock-pickers have managed to consistently outperform the S&P 500. One such pro is Mark Boyer, who every year culls 40 stocks with the potential to beat the benchmark index. Here are his top five picks for 2010.

Bristol-Myers Squibb's Kidney Transplant Drug Gets a Nod

An FDA advisory panel recommended approval of Bristol-Myers Squibb's belatacept, an experimental drug used in kidney transplants -- with at least one caveat. It recommended further long-term studies after a full FDA approval.

Health-Care Sector Appears to Rally As Reform Chances Dim

President Obama can't be pleased by the loss of a Democratic Senate seat which jeopardizes passage of his cherished health-care reform. The news, however, appears to have fueled a mini stock rally in the health-care and pharma sectors wary of how any reform would affect their businesses. The uptrend is expected to continue.

Pharmaceutical Companies Assist Haiti with Medicine, Cash

As Haiti reels from the 7.0 earthquake that devastated its capital, Port-au-Prince, on Tuesday, relief efforts are beginning to make headway. The crisis also gives Big Pharma ample opportunity to help relief efforts, with contributions coming from Merck, GlaxoSmithKline, Abbott, and other heavy-hitters.

Mead Johnson May Be Buyout Bait

Bristol-Myers Squibb sold its controlling 83% stake in December, and Mead is attracting new attention not just because of its global dominance in infant formula and children's nutritional products. Nestle and Danone are rumored to be interested suitors.